![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » BioSyntech Files ITA Application for Canadian BST-CarGel Trial
BioSyntech Files ITA Application for Canadian BST-CarGel Trial
May 11, 2005
BioSyntech is seeking approval from Health Canada to begin a pivotal clinical trial for its cartilage repair device, BST-CarGel. Extensive documentation, encompassing product design and analysis of risk, 18 preclinical safety and efficacy studies, and clinical knowledge to date was recently sent to Health Canada, Therapeutic Products Directorate, Medical Device Branch, to support the application for investigational testing authorization (ITA).
Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=524520XSL_NEWSML_TO_NEWSML_WEB.xml)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct